As the number of Canadians living with dementia rises, so does the demand for dementia-related care across the country. CADTH facilitated a roundtable discussion to hear about clinicians’ perspectives...

There are not very many effective treatment options for Alzheimer disease and most of the options have side effects for many people, and temporarily reduce symptoms rather than delay disease...

Trace amine-associated receptor 1 (TAAR1) agonists are an emerging drug class in the treatment of schizophrenia. Currently available antipsychotic therapies for schizophrenia act by blocking dopamine...

Alzheimer disease is a progressive neurologic condition that leads to the decline of cognitive functioning and eventual death. Proposed causes of Alzheimer disease include the amyloid hypothesis...

As the population ages, decision-makers are faced with different choices of care models for people diagnosed with dementia. Recent media reports have focused on dementia villages, first developed at...

Summary Probuphine is the first subdermal implant for the maintenance treatment of opioid use disorder designed to provide continuous, non-fluctuating, blood levels of buprenorphine for up to six...